1. Generics Bulletin
  2. >>Leadership

Who’s Hired? O’Brien To Replace Richards As Mayne Pharma CEO

Plus Hikma Appoints New Board Members And Mallinckrodt Welcomes New CCO

 
• By Chloe Kent

Mayne Pharma has announced the appointment of pharma industry veteran Shawn O’Brien as CEO, replacing outgoing delegate Scott Richards. Plus, Hikma has appointed two new female board members, in line with gender diversity targets set by the UK Financial Conduct Authority.

Shawn O'Brien headshot
Shawn O'Brien has over 35 years of pharmaceutical industry experience • Source: Mayne Pharma

Following the retirement of former CEO and managing director Scott Richards, Mayne Pharma has appointed former AstraZeneca executive Shawn O’Brien as successor to the role. Richards, who stepped down from the role and from his position on the board on 1 October, will remain with Mayne until 30 November to ensure a well-managed transition to the new CEO.

O’Brien has over 35 years of pharmaceutical industry experience

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

More from Generics Bulletin

‘I’ll Be Happy When We Have 40-Plus Assets’ – Sandoz Builds Up Biosimilars

 
• By Dave Wallace

With biosimilars playing an increasingly important role in Sandoz’s business, the firm’s first-quarter results call saw management lay out the latest key developments. Meanwhile, the company also addressed the issue of US tariffs, voicing optimism over both future developments as well as its ability to weather current measures.

Teva To Slash Thousands Of Jobs And Shut More Sites Under $700m Savings Plan

 
• By Dean Rudge

Teva’s plans to generate net savings of $700m by 2027 have been described by the firm as a journey and not a destination, with the suggestion that “this era of cost efficiency, harmonization, frugality will continue.”

Tetris Deal Falls Into Place For UK’s Aspire

 
• By Dave Wallace

Niche generics company Aspire Pharma has struck a deal to acquire a portfolio of products from fellow UK firm Tetris Pharma as it is wound up, paying Tetris parent Arecor £0.5m for UK distribution rights and inventory.